Patents by Inventor Sara S. Hadida Ruah

Sara S. Hadida Ruah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240294512
    Abstract: Compounds of formula I and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.
    Type: Application
    Filed: June 3, 2022
    Publication date: September 5, 2024
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Elizabeth Mary BECK, Robert PULLIN, Gorka ETXEBARRIA JARDI, Dean STAMOS, Yvonne SCHMIDT, Joseph PONTILLO, Stephen Andrew THOMSON, David Matthew SHAW, Nadia M. AHMAD, Lidio Marx CARVALHO MEIRELES, Sarah SKERRATT, Sara S. HADIDA RUAH, Timothy Donald NEUBERT, Dennis James HURLEY, Steven John DURRANT, Christopher WRAY, Anisa Nizarali VIRANI, Kiri NORTH, Bhairavi GALAN, Ronald Marcellus KNEGTEL, Ewa Iwona CHUDYK, Joanne Louise PINDER, Bruno Artur SOUSA, Francoise PIERARD
  • Publication number: 20240182455
    Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.
    Type: Application
    Filed: October 20, 2023
    Publication date: June 6, 2024
    Inventors: Elizabeth Mary Beck, Steven John Durrant, Sarah Skerratt, Robert Pullin, Gorka Etxebarria Jardi, David Matthew Shaw, Nadia M. Ahmad, Christopher Wray, Anisa Nizarali Virani, Kiri North, James Dodd, Michael Edward O'Donnell, Bhairavi Galan, Ronald Marcellus Knegtel, Ewa Iwona Chudyk, Joanne Louise Pinder, Stephen Andrew Thomson, Lidio Marx Carvalho Meireles, Dean Stamos, Yvonne Schmidt, Joseph Pontillo, Sara S. Hadida Ruah, Timothy Donald Neubert, Dennis James Hurley, Jinglan Zhou
  • Publication number: 20240092766
    Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Application
    Filed: February 10, 2023
    Publication date: March 21, 2024
    Inventors: Sara S. HADIDA RUAH, Peter D.J. GROOTENHUIS, Fredrick VAN GOOR, Jinglan ZHOU, Brian BEAR, Mark T. MILLER, Jason McCARTNEY, Mehdi Michel Jamel NUMA, Xiaoqing YANG
  • Patent number: 11919887
    Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.
    Type: Grant
    Filed: November 8, 2022
    Date of Patent: March 5, 2024
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Steven John Durrant, Nadia M. Ahmad, Elizabeth Mary Beck, Lidio Marx Carvalho Meireles, Ewa Iwona Chudyk, Gorka Etxebarria Jardi, Bhairavi Galan, Sara S. Hadida Ruah, Dennis James Hurley, Ronald Marcellus Knegtel, Timothy Donald Neubert, Joanne Louise Pinder, Joseph Pontillo, Robert Pullin, Yvonne Schmidt, David Matthew Shaw, Sarah Skerratt, Dean Stamos, Stephen Andrew Thomson, Anisa Nizarali Virani, Christopher Wray
  • Patent number: 11834441
    Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: December 5, 2023
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Steven John Durrant, Nadia Ahmad, Elizabeth Mary Beck, Lidio Marx Carvalho Meireles, Ewa Iwona Chudyk, Gorka Etxebarria Jardi, Bhairavi Galan, Sara S. Hadida Ruah, Dennis James Hurley, Ronald Marcellus Knegtel, Timothy Donald Neubert, Joanne Louise Pinder, Joseph Pontillo, Robert Pullin, Yvonne Schmidt, David Matthew Shaw, Sarah Skerratt, Dean Stamos, Stephen Andrew Thomson, Anisa Nizarali Virani, Christopher Wray
  • Patent number: 11827627
    Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: November 28, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Elizabeth Mary Beck, Steven John Durrant, Sarah Skerratt, Robert Pullin, Gorka Etxebarria Jardi, David Matthew Shaw, Nadia M. Ahmad, Christopher Wray, Anisa Nizarali Virani, Kiri North, James Dodd, Michael Edward O'Donnell, Bhairavi Galan, Ronald Marcellus Knegtel, Ewa Iwona Chudyk, Joanne Louise Pinder, Stephen Andrew Thomson, Lidio Marx Carvalho Meireles, Dean Stamos, Yvonne Schmidt, Joseph Pontillo, Sara S. Hadida Ruah, Timothy Donald Neubert, Dennis James Hurley, Jinglan Zhou
  • Publication number: 20230286961
    Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.
    Type: Application
    Filed: November 8, 2022
    Publication date: September 14, 2023
    Inventors: Steven John Durrant, Nadia M. Ahmad, Elizabeth Mary Beck, Lidio Marx Carvalho Meireles, Ewa Iwona Chudyk, Gorka Etxebarria Jardi, Bhairavi Galan, Sara S. Hadida Ruah, Dennis James Hurley, Ronald Marcellus Knegtel, Timothy Donald Neubert, Joanne Louise Pinder, Joseph Pontillo, Robert Pullin, Yvonne Schmidt, David Matthew Shaw, Sarah Skerratt, Dean Stamos, Stephen Andrew Thomson, Anisa Nizarali Virani, Christopher Wray
  • Patent number: 11639347
    Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Grant
    Filed: February 22, 2021
    Date of Patent: May 2, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Sara S. Hadida Ruah, Peter D. J. Grootenhuis, Fredrick Van Goor, Jinglan Zhou, Brian Bear, Mark T. Miller, Jason McCartney, Mehdi Michel Jamel Numa, Xiaoqing Yang
  • Publication number: 20220411410
    Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Application
    Filed: February 22, 2021
    Publication date: December 29, 2022
    Inventors: Sara S. HADIDA RUAH, Peter D.J. GROOTENHUIS, Fredrick VAN GOOR, Jinglan Zhou, Brian BEAR, Mark T. MILLER, Jason McCARTNEY, Mehdi Michel Jamel NUMA, Xiaoqing YANG
  • Publication number: 20220153729
    Abstract: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Application
    Filed: June 29, 2021
    Publication date: May 19, 2022
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Sara S. HADIDA RUAH, Matthew M. HAMILTON, Mark MILLER, Peter D.J. GROOTENHUIS
  • Patent number: 11084804
    Abstract: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: August 10, 2021
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Sara S. Hadida Ruah, Matthew M. Hamilton, Mark Miller, Peter D. J. Grootenhuis
  • Patent number: 10975061
    Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: April 13, 2021
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Sara S. Hadida Ruah, Peter D. J. Grootenhuis, Fredrick Van Goor, Jinglan Zhou, Brian Bear, Mark T. Miller, Jason McCartney, Mehdi Michel Jamel Numa, Xiaoqing Yang
  • Publication number: 20210024505
    Abstract: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Application
    Filed: February 13, 2020
    Publication date: January 28, 2021
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Sara S. HADIDA RUAH, Matthew M. HAMILTON, Mark MILLER, Peter D.J. GROOTENHUIS
  • Patent number: 10738030
    Abstract: The present disclosure features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, W, X, Z, n, p, and Rings A and B are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present disclosure also features pharmaceutical compositions, method of treating, and kits thereof.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: August 11, 2020
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Brian Bear, Jeremy Clemens, Thomas Cleveland, Timothy Richard Coon, Peter Diederik Jan Grootenhuis, Bryan A. Frieman, Sara S. Hadida Ruah, Haripada Khatuya, Paul J. Krenitsky, Mark Thomas Miller, Alina Silina, Johnny Uy, Jinglan Zhou
  • Patent number: 10626111
    Abstract: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTC”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: April 21, 2020
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Sara S. Hadida Ruah, Matthew M. Hamilton, Mark Miller, Peter D. J. Grootenhuis
  • Publication number: 20200115366
    Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Application
    Filed: February 15, 2019
    Publication date: April 16, 2020
    Inventors: Sara S. HADIDA RUAH, Peter D.J. GROOTENHUIS, Fredrick VAN GOOR, Jinglan Zhou, Brian BEAR, Mark T. MILLER, Jason McCARTNEY, Mehdi Michel Jamel NUMA, Xiaoqing YANG
  • Publication number: 20190322650
    Abstract: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Application
    Filed: November 21, 2018
    Publication date: October 24, 2019
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Sara S. HADIDA RUAH, Matthew M. HAMILTON, Mark MILLER, Peter D.J. GROOTENHUIS
  • Patent number: 10239867
    Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: March 26, 2019
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Sara S. Hadida Ruah, Peter D. J. Grootenhuis, Fredrick Van Goor, Jinglan Zhou, Brian Bear, Mark T. Miller, Jason McCartney, Mehdi Michel Jamel Numa, Xiaoqing Yang
  • Publication number: 20190055220
    Abstract: The present disclosure features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, W, X, Z, n, p, and Rings A and B are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present disclosure also features pharmaceutical compositions, method of treating, and kits thereof.
    Type: Application
    Filed: March 31, 2017
    Publication date: February 21, 2019
    Inventors: Brian Bear, Jeremy Clemens, Thomas Cleveland, Timothy Richard Coon, Peter Diederik Jan Grootenhuis, Bryan A. Frieman, Sara S. Hadida Ruah, Haripada Khatuya, Paul J. Krenitsky, Mark Thomas Miller, Alina Silina, Johnny Uy, Jinglan Zhou
  • Publication number: 20180282311
    Abstract: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Application
    Filed: June 1, 2016
    Publication date: October 4, 2018
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Sara S. HADIDA RUAH, Matthew M. Hamilton, Mark Miller, Peter D.J. Grootenhuis, Brian Bear, Jason McCartney, Jinglan Zhou